Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.9%

2 terminated out of 29 trials

Success Rate

92.0%

+5.5% vs benchmark

Late-Stage Pipeline

48%

14 trials in Phase 3/4

Results Transparency

35%

8 of 23 completed with results

Key Signals

8 with results92% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (3)
P 1 (5)
P 2 (2)
P 3 (8)
P 4 (6)

Trial Status

Completed23
Unknown3
Terminated2
Not Yet Recruiting1

Trial Success Rate

92.0%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT05526716Phase 3CompletedPrimary

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05412030Phase 2Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT06136832Not ApplicableCompletedPrimary

Pneumonia Vaccine Education Intervention Study

NCT06562790Phase 1CompletedPrimary

Study of Gamma PN3 in the Elderly

NCT04909268CompletedPrimary

Prevention of Missed Opportunities for HIV Diagnosis by Promoting HIV Testing of Patients With Pneumococcal Pneumonia at Nice University Hospital (PneumoVIH)

NCT05420961Phase 3CompletedPrimary

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05799976Not ApplicableCompletedPrimary

Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure

NCT02961231Phase 4CompletedPrimary

Evaluation of PCV Schedules in a Naive Population in Vietnam

NCT04923035UnknownPrimary

Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation

NCT04168190Phase 1CompletedPrimary

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04559204Phase 4Completed

Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

NCT03896477Phase 3CompletedPrimary

Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants

NCT03315403CompletedPrimary

Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN"

NCT04790851Phase 4Completed

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

NCT05079152Phase 4Unknown

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

NCT03058211TerminatedPrimary

Myocardial Injury and Severe Pneumococcal Pneumonia

NCT03950856Phase 3Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT04464291Not ApplicableCompletedPrimary

An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 Years

NCT03197376Phase 3CompletedPrimary

Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants

NCT04357522Phase 3Not Yet RecruitingPrimary

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

Scroll to load more

Research Network

Activity Timeline